SENSCIS trial shows nintedanib reduces the decline of lung function in patients with limited cutaneous systemic sclerosis and ILD
According to research published in Rheumatology, nintedanib reduces the decline of lung functionality in patients with limited cutaneous systemic sclerosis (SSc) and interstitial lung disease …